5 days ago
8
Legend Biotech Corporation (NASDAQ:LEGN) ranks among the most oversold biotech stocks to put in. On November 12, William Blair expert Sami Corwin reiterated his Hold standing for Legend Biotech Corporation (NASDAQ:LEGN) shares. The expert mentioned the company’s Carvykti, which has seen a important boost successful revenue, owing to its acceptance successful third-line settings. However, this maturation fell somewhat abbreviated of the analysts’ estimates.
Legend Biotech Corporation (NASDAQ:LEGN) has flooded erstwhile manufacturing capableness concerns, is presently fulfilling marketplace demand, and plans further enlargement to importantly boost dosing capableness by 2026. Despite these encouraging advances, the amended Carvykti label, which includes caller information warnings, poses imaginable issues.
On the aforesaid time arsenic the expert coverage, Legend Biotech Corporation (NASDAQ:LEGN) published its third-quarter net for 2025, which were mixed and fell abbreviated of marketplace forecasts. The institution reported net per stock of -$0.05, somewhat little than the expected -$0.044. Meanwhile, gross fell abbreviated of the expected $274.72 million, coming successful astatine $272.33 million.
Legend Biotech Corporation (NASDAQ:LEGN) is simply a clinical-stage institution that develops, discovers, manufactures, and commercializes caller therapies for oncology and different indications.
While we admit the imaginable of LEGN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
Disclosure: None. This nonfiction is primitively published at Insider Monkey.
.png)
English (CA) · 
English (US) · 
Spanish (MX) ·